Core Viewpoint - VitalHub Corp. has changed its auditor from MNP LLP to Ernst & Young LLP effective September 9, 2025 [1][2]. Auditor Change - The change was initiated at the request of the Company, leading to the resignation of the Former Auditor and the appointment of the Successor Auditor [2]. - The new auditor will serve until the close of the Company's next Annual General Meeting [2]. Audit Reports - There were no reservations in the Former Auditor's audit reports for the two most recently completed fiscal years [3]. - No reportable events occurred between the Company and the Former Auditor as defined in National Instrument 51-102 [3]. Compliance and Documentation - The Notice of Change of Auditor, along with required letters from both auditors, has been reviewed by the Company's Board of Directors and Audit Committee, and filed on SEDAR+ [4]. Company Overview - VitalHub is a leading software company focused on health and human services, serving over 1,000 clients globally [5]. - The Company has a growth strategy that includes organic opportunities and an aggressive M&A plan [5]. - VitalHub is headquartered in Toronto and employs over 500 people worldwide, including a lab in Sri Lanka [5].

The Common Shares were qualified for distribution by a prospectus supplement dated August 15, 2025 to the base shelf prospectus dated July 23, 2025, filed in the provinces of Ontario, British Columbia and Alberta. The Common Shares were also sold in the United States on a private placement basis pursuant to an exemption from the registration requirements of the United States Securities Act of 1933 (the "U.S. Securities Act"). The Common Shares have been conditionally approved for listing on the Toronto Stoc ...

Core Points - VitalHub Corp. has filed a prospectus supplement for a public offering of 5,118,111 common shares at a price of $12.70 per share, aiming for gross proceeds of approximately $65 million, with an additional 767,717 shares available through an over-allotment option for about $9.75 million [1][2][3] Group 1 - The offering is expected to close on or about August 20, 2025, pending regulatory approval from the Toronto Stock Exchange [2] - The common shares will be sold in Canada and may also be offered in the United States under private placement exemptions [3] - The prospectus and its amendments are accessible through SEDAR+, and interested investors can obtain copies from Cormark Securities Inc. [4] Group 2 - VitalHub is a leading software company focused on health and human services, serving over 1,300 clients globally with a product suite that includes electronic health records and operational intelligence [7] - The company has a growth strategy that includes both organic opportunities and an aggressive M&A plan, with a workforce of over 600 employees [7]

Core Insights - VitalHub Corp. reported a significant increase in Annual Recurring Revenue (ARR), which rose by 55% year-over-year to $79.6 million [1][10] - Total revenue for the second quarter of 2025 increased by 47% year-over-year to $23.9 million [1][8] - Adjusted EBITDA also saw a substantial rise, up 50% year-over-year to $6.3 million [1][8] Financial Performance - For the three months ended June 30, 2025, revenue was $23,857,548, compared to $16,237,605 in the same period last year, marking a 47% increase [7][8] - For the six months ended June 30, 2025, total revenue reached $45,532,514, up 45% from $31,494,396 in the prior year [7][8] - Gross profit as a percentage of revenue remained stable at 81% for both Q2 2025 and Q2 2024 [8][9] Growth Drivers - The ARR growth of $28,305,511 or 55% from $51,283,570 at June 30, 2024, was driven by organic growth of $7,329,129 (14%) and acquisition growth of $18,470,000 (36%) [8][10] - The company closed significant acquisitions, including Novari Health and Induction, which are expected to enhance its product offerings in electronic referral and patient engagement solutions [3][8] Cash Position - As of June 30, 2025, VitalHub had a cash balance of $94,008,665, an increase from $56,574,904 at the end of 2024 [10][11] - The company arranged a $15 million loan for acquisition financing, which was fully repaid after the quarter-end [8][10] Strategic Outlook - VitalHub aims to continue its international expansion, supported by a robust cash position and a strong ARR [3][11] - The company is focused on integrating its recent acquisitions to build a consolidated financial profile [3][11]

Core Viewpoint - VitalHub Corp. is set to release its financial results for Q2 2025 on August 7, 2025, with a conference call scheduled for August 8, 2025, hosted by CEO Dan Matlow and CFO Brian Goffenberg [1] Company Overview - VitalHub is a leading software company focused on empowering health and human services providers globally [2] - The company's product suite includes electronic health records, operational intelligence, and workforce automation solutions, serving over 1,000 clients across the UK, Canada, and other regions [2] - VitalHub employs over 500 individuals globally and has a dedicated Innovations Lab located in Sri Lanka [2] - The company has a two-pronged growth strategy that includes targeting organic growth opportunities within its product suite and pursuing an aggressive mergers and acquisitions (M&A) plan [2]

Core Points - Vitalhub Corp. held its annual general meeting on June 27, 2025, where all director nominees were elected and MNP LLP was appointed as auditors [1][3] Voting Results - Total shares voted were 33,721,314, representing 60.45% of the total shares issued and outstanding, which is 55,784,972 [1] - Election of Directors: - Barry Tissenbaum received 27,796,480 votes (83.01%) - Roger Dent received 22,227,480 votes (66.38%) - Stephen Garrington received 33,334,105 votes (99.55%) - Dan Matlow received 33,209,025 votes (99.18%) - Francis Shen received 24,660,909 votes (73.65%) - Tony Shen received 27,960,184 votes (83.50%) [2] - Appointment of Auditors: - MNP LLP received 33,564,368 votes (99.53%) for appointment as auditors [4] Company Overview - VitalHub is a leading software company focused on health and human services, offering a product suite that includes electronic health records and operational intelligence [5] - The company serves over 1,000 clients across the UK, Canada, and other regions, and has a growth strategy that includes both organic opportunities and an aggressive M&A plan [5]

Core Insights - VitalHub Corp. reported a strong start to 2025 with significant growth in Annual Recurring Revenue (ARR) and total revenue, indicating robust business performance and strategic positioning in the health and human services software market [3][6]. Financial Performance - ARR increased by 54% year-over-year to $73.7 million as of March 31, 2025, compared to $47.8 million in the same period last year [6][7]. - Total revenue for the first quarter of 2025 was $21.7 million, reflecting a 42% increase from $15.3 million in the prior year [6][7]. - Adjusted EBITDA rose by 39% year-over-year to $5.6 million, representing 26% of total revenue [6][7]. Growth Drivers - The ARR growth was driven by organic growth of $6.7 million (14%) and acquisition growth of $16.8 million (35%) over the past year [6]. - The company ended the first quarter with a cash balance exceeding $90 million, positioning it well for future acquisitions [3][6]. Strategic Initiatives - VitalHub is pursuing a potential cash acquisition of UK-based Induction Healthcare Group PLC, valued at approximately £9.7 million ($18 million), expected to close in Q3 2025 [3][6]. - The company maintains a disciplined approach to acquisitions, focusing on opportunities that offer strategic value and improved pricing [3]. Operational Highlights - The gross profit margin was 80% for the first quarter of 2025, slightly down from 81% in the prior year [7]. - The company serves over 1,000 clients globally, with a comprehensive product suite that includes electronic health records and operational intelligence solutions [8][9].

Core Viewpoint - VitalHub Corp. is set to release its financial results for Q1 2025 on May 8, 2025, followed by a conference call on May 9, 2025, hosted by CEO Dan Matlow and CFO Brian Goffenberg [1] Company Overview - VitalHub is a leading software company focused on empowering health and human services providers globally [2] - The company offers a comprehensive product suite that includes electronic health records, operational intelligence, and workforce automation solutions, serving over 1,000 clients across the UK, Canada, and other regions [2] - VitalHub employs over 500 individuals globally and has a dedicated Innovations Lab located in Sri Lanka [2] - The company has a robust growth strategy that includes targeting organic opportunities within its product suite and pursuing an aggressive M&A plan [2]

Core Viewpoint - VitalHub Corp. has announced a cash acquisition of Induction Healthcare Group PLC, valuing Induction at approximately £9.7 million, with each shareholder entitled to receive £0.10 in cash for each share held [1] Company Overview - Induction provides software solutions that enhance care delivery and patient journeys in hospitals, allowing healthcare providers to deliver care both remotely and face-to-face [3][16] - Key products include Zesty, a patient engagement platform, and Attend Anywhere, a video consultation platform [4][5] Financial Performance - For FY24, Induction reported revenues of £14.4 million, a gross margin of 78.4%, and an adjusted EBITDA loss of £0.3 million [6] - For H1 FY25, revenues were £5.4 million, with a gross margin of 78.2% and an adjusted EBITDA loss of £0.9 million [7] Strategic Rationale - VitalHub views Induction's Zesty platform as complementary to its existing offerings, aiming to enhance product diversity and improve patient outcomes [8] - The acquisition is expected to expand VitalHub's market reach in the UK, Europe, Canada, the Middle East, and Australia [9] - Induction is anticipated to benefit from being part of a larger, well-capitalized enterprise, enabling effective implementation of strategic initiatives [10] Acquisition Details - The acquisition will be executed through a court-approved scheme of arrangement, requiring approval from Induction shareholders and the Court [11][12] - Induction's directors recommend shareholders vote in favor of the scheme, with irrevocable commitments received for approximately 44.3% of Induction's shares [13] - The transaction is expected to close by July 31, 2025, with a long stop date of September 30, 2025 [13]